A
0.026
0.00 (0.00%)
| Previous Close | 0.026 |
| Open | 0.026 |
| Volume | 3,043,638 |
| Avg. Volume (3M) | 13,999,521 |
| Market Cap | 76,570,000 |
| Price / Book | 3.98 |
| 52 Weeks Range | |
| Earnings Date | 30 Aug 2024 |
| Profit Margin | -131.34% |
| Operating Margin (TTM) | -17.76% |
| Diluted EPS (TTM) | -0.010 |
| Quarterly Revenue Growth (YOY) | 132.30% |
| Total Debt/Equity (MRQ) | 1.62% |
| Current Ratio (MRQ) | 13.91 |
| Operating Cash Flow (TTM) | -16.95 M |
| Levered Free Cash Flow (TTM) | -12.20 M |
| Return on Assets (TTM) | -45.37% |
| Return on Equity (TTM) | -78.81% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (AU) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | ACTINOGEN FPO [ACW] | - | - |
AIStockmoo Score
-0.3
| Analyst Consensus | 0.0 |
| Insider Activity | NA |
| Price Volatility | -1.0 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | 0.0 |
| Average | -0.25 |
|
Actinogen Medical Ltd is a biotechnology company. The company develops drugs for Alzheimer's disease and the cognitive decline associated with other neurological diseases. It is focused on the clinical development of Xanamem, an oral medication for neurological diseases amenable to its mechanism of lowering cortisol in brain cells. Geographically, the company's income is derived in Australia. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 15.36% |
| % Held by Institutions | 7.29% |
No data within this time range.
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |